Brickell Biotech Inc
Change company Symbol lookup
Select an option...
BBI Brickell Biotech Inc
VTOL Bristow Group Inc
VTRS Viatris Inc
MSFT Microsoft Corp
NTB Bank of N T Butterfield & Son Ltd
CHN China Fund, Inc.
IGR CBRE Global Real Estate Income Fund
SURRY Sun Art Retail Group Ltd
VPV Invesco Pennsylvania Value Municipal Income Trust
HLBZ Helbiz Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company engaged in developing prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. The Company’s pipeline combines several development-stage candidates and a cutting-edge platform with autoimmune and inflammatory disorders program for the treatment of primary axillary hyperhidrosis. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Its lead development-stage program, BBI-02, is a Phase I ready, highly selective, and orally bioavailable DYRK1A inhibitor that has demonstrated in various preclinical models, including atopic dermatitis and rheumatoid arthritis. BBI-10, the Company’s lead early-stage STING inhibitor candidate, is a novel, potent, and orally available covalent STING inhibitor that specifically targets the palmitoylation site of STING, which allows to inhibit both wild-type STING and gain-of-function mutants.

Premarket

Last Trade
Delayed
$3.60
0.10 (2.86%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$3.50
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
3,007

10-day average volume:
472,875
3,007

SHAREHOLDER ALERT: CDNA ET APPS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

12:15 pm ET June 29, 2022 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / June 29, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

CareDx, Inc. (NASDAQ:CDNA)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/caredx-inc-loss-submission-form?prid=29364&wire=1

Lead Plaintiff Deadline: July 22, 2022

This lawsuit is on behalf of all persons or entities who purchased CareDx common stock between February 24, 2021, and May 5, 2022.

Allegations against CDNA include that: (1) defendants had engaged in a variety of improper and illegal schemes to inflate testing services revenue and demand, including pushing a surveillance protocol through inaccurate marketing materials, offering extravagant inducements or kickbacks to physicians and other providers, and improperly bundling expensive testing services with other blood tests as part of the Company's RemoTraC service for remote, home-based, blood-drawing; (2) these practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny; (3) these practices rendered the Company's testing services revenue reported throughout the class period artificially inflated; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Energy Transfer LP (NYSE:ET)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/energy-transfer-lp-loss-submission-form-2?prid=29364&wire=1

Lead Plaintiff Deadline: August 2, 2022

This lawsuit is on behalf of persons who purchased or otherwise acquired common shares of Energy Transfer stock between April 13, 2017 and December 20, 2021, both dates inclusive.

Allegations against ET include that: (a) Energy Transfer had inadequate internal controls and procedures to prevent contractors from engaging in illegal conduct with regards to drilling activities, and/or failed to properly mitigate known issues related to such controls and procedures; (b) Energy Transfer, through its subsidiary Rover Pipeline, LLC, hired a third-party contractor to conduct Horizontal Directional Drilling Activities for the Rover Pipeline Project, whose conduct of adding illegal additives in the drilling mud caused severe pollution near the Tuscarawas River when a large inadvertent release took place on April 13, 2017; (c) Energy Transfer continually downplayed its potential civil liabilities when the Federal Energy Regulatory Commission ("FERC") was actively investigating the Energy Transfer's wrongdoing related to the April 13 release and consistently provided it with updated information about FERC's findings on this matter.

Digital Turbine, Inc. (NASDAQ:APPS)

If you suffered a loss, contact us at:https://www.wongesq.com/pslra-1/digital-turbine-inc-loss-submission-form?prid=29364&wire=1

Lead Plaintiff Deadline: August 5, 2022

Class Period: August 9, 2021 - May 17, 2022

Allegations against APPS include that: (1) the Company's recent acquisitions, AdColony and Fyber, act as agents in certain of their respective product lines; (2) as a result, revenues for those product lines must be reported net of license fees and revenue share, rather than on a gross basis; (3) the Company's internal control over financial reporting as to revenue recognition was deficient; and (4) as a result of the foregoing, the Company's net revenues was overstated throughout fiscal 2022; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

The Law Offices of Vincent Wong, Wednesday, June 29, 2022, Press release picture

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.

39 East Broadway

Suite 304

New York, NY 10002

Tel. 212.425.1140

Fax. 866.699.3880

E-Mail: vw@wongesq.com

SOURCE : The Law Offices of Vincent Wong





View source version on accesswire.com:

https://www.accesswire.com/706964/SHAREHOLDER-ALERT-CDNA-ET-APPS-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines



comtex tracking

COMTEX_409428953/2457/2022-06-29T12:15:54

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.